Entera Bio (ENTX) Debt to Equity (2017 - 2026)
Entera Bio (ENTX) recorded quarterly Debt to Equity of $0.05 in Q1 2026, up 76.86% on a QoQ basis from $0.03 in Q4 2025, and up 99.64% year-over-year from $0.03 in Q1 2025.
Entera Bio (ENTX) Debt to Equity (2017 - 2026) Analysis & Trends
Entera Bio has disclosed Debt to Equity across 3 years of filings, most recently posting $0.05 for Q1 2026.
- Quarterly Debt to Equity rose 99.64% year-over-year to $0.05 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $0.05 (up 99.64% YoY) and the FY2025 annual result came in at $0.03, changed N/A from the prior year.
- Debt to Equity rose to $0.05 in Q1 2026, from $0.03 in the prior quarter.
- Over five years, Debt to Equity peaked at $0.05 in Q1 2026 and troughed at $0.03 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt/Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | - |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | 0.32 |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | - |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | - |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | - |
| 10 | Entera Bio | 57.79 Mn | 53.65 Mn | - | 0.05 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.05 |
| Dec 31, 2025 | 0.03 |
| Sep 30, 2025 | 0.03 |
| Jun 30, 2025 | 0.03 |
| Mar 31, 2025 | 0.03 |
| Dec 31, 2017 | -0.12 |